Vigora
Vigora Price range: $ 46,00 through $ 220,00
Back to products
Vilitra
Vilitra Price range: $ 72,00 through $ 513,00

Vilafinil

Price range: $ 65,00 through $ 375,00

Vilafinil is a potent wakefulness-promoting medication designed to help individuals manage excessive daytime sleepiness effectively. It works by influencing specific natural substances in the brain that regulate the sleep-wake cycle to ensure alertness throughout the day. This medication is primarily indicated for treating adults diagnosed with narcolepsy, obstructive sleep apnea, or shift work sleep disorder. By promoting sustained wakefulness, Vilafinil helps users maintain focus and productivity during their active hours. Experience reliable support for a more alert and energetic lifestyle with this high-quality generic alternative.

Active substance: Modafinil
SKU: Vilafinil Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Vilafinil belongs to a class of central nervous system agents known as wakefulness-promoting medications. It is prescribed under medical supervision to manage excessive sleepiness associated with diagnosed sleep disorders, including narcolepsy, obstructive sleep apnea, and shift work disorder.

Containing modafinil as its active pharmaceutical ingredient, Vilafinil is regulated as a Schedule IV controlled substance under federal law due to potential risk for dependence or misuse. Dispensed strictly by prescription, its administration requires careful clinical evaluation and routine monitoring by a qualified healthcare provider.

Property Details
Active ingredient Modafinil
Therapeutic class Central Nervous System Agent / Wakefulness-Promoting Agent
Dosage form Oral Tablet
Route of administration Oral
Primary purpose Management of excessive sleepiness (Narcolepsy, OSA, SWD)
Prescription status Prescription required (Rx / Controlled Substance)

Clinical Profile and Pharmacological Mechanisms

How the drug works

The precise mechanism by which Vilafinil promotes wakefulness remains fully unelucidated, but its pharmacological profile differs significantly from conventional sympathomimetic central nervous system stimulants such as amphetamines or methylphenidate. Modafinil binds to the dopamine transporter (DAT) and inhibits dopamine reuptake, resulting in an increase in extracellular dopamine concentrations within specific brain regions, particularly the hypothalamus and striatum. Additionally, the drug modulates other neurotransmitter systems, increasing extracellular levels of histamine, norepinephrine, and glutamate while decreasing gamma-aminobutyric acid (GABA) release. Unlike classic stimulants, it demonstrates lower potential for widespread neuronal activation, targeting brain circuits primarily involved in the regulation of sleep and wakefulness states.

Main uses

In clinical practice, Vilafinil is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy, a chronic neurological condition characterized by sleep attacks and fragmented nighttime sleep. It is also indicated as an adjunctive treatment for excessive sleepiness in patients with obstructive sleep apnea (OSA) who are concurrently receiving continuous positive airway pressure (CPAP) or other primary therapies. Furthermore, it is prescribed for shift work disorder (SWD) in individuals experiencing severe sleepiness during night shifts or rotating schedules. Any application outside these FDA-approved indications–such as off-label use for general fatigue, age-related cognitive decline, or attention deficit hyperactivity disorder (ADHD)–is considered off-label, lacks standardized dosing protocols, and requires explicit clinical oversight.

How it’s absorbed and eliminated

Vilafinil is rapidly absorbed following oral administration, achieving peak plasma concentration within approximately 2 to 4 hours post-ingestion. Administration with food does not alter the overall extent of absorption, though it may delay peak plasma levels by approximately one hour. The drug exhibits wide distribution throughout body tissues with plasma protein binding of approximately 60%, primarily to albumin. Hepatic metabolism constitutes the primary pathway of elimination, largely mediated by cytochrome P450 3A4 (CYP3A4) and CYP3A5 enzymes, converting the drug into inactive metabolites including modafinil acid and modafinil sulfone. The elimination half-life ranges between 12 and 15 hours under steady-state conditions. Excretion occurs predominantly through renal pathways, with less than 10% of the parent drug excreted unchanged in urine.

Dosing, Safety Precautions, and Practical Management

Dosing schedule

The recommended standard dosage of Vilafinil for patients with narcolepsy or obstructive sleep apnea is 200 mg taken orally as a single daily dose in the morning. For shift work disorder, the standard administration is 200 mg taken approximately one hour prior to the start of the work shift. Dosage adjustments are mandatory in specific patient populations: patients with severe hepatic impairment require a reduction of the standard dose by 50% (to 100 mg daily). In elderly populations, lower dosages may be considered due to age-related reductions in renal and hepatic clearance. Tablets should be swallowed whole with water and may be taken with or without food.

Important precautions: Before initiating treatment, patients must undergo cardiovascular screening. Vilafinil is not recommended for individuals with a history of severe left ventricular hypertrophy or severe mitral valve prolapse experiencing central nervous system stimulant effects. Blood pressure and heart rate monitoring are recommended throughout therapy, particularly in patients with hypertension. Caution is warranted in individuals with a history of psychiatric disorders, including psychosis, mania, or severe depression, as wakefulness-promoting agents may exacerbate psychiatric symptoms. Pediatric safety and efficacy in patients under 17 years of age have not been established.

What side effects may occur: Treatment with Vilafinil can produce mild to severe adverse reactions. The most common side effects observed in clinical evaluation include headache, nausea, nervousness, rhinitis, anxiety, insomnia, dizziness, and gastrointestinal disturbances such as dyspepsia. Severe adverse reactions, though infrequent, require immediate medical attention. These include severe cutaneous reactions such as Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), severe angioedema, chest pain, irregular cardiac rhythm, and psychiatric symptoms such as hallucinations, aggression, or suicidal ideation.

What not to combine: Modafinil alters the metabolic activity of several hepatic enzymes, leading to significant drug-drug interactions. It induces CYP3A4 activity, which substantially decreases the blood concentrations and efficacy of hormonal contraceptives (including oral birth control pills, implants, and intrauterine devices). Alternative or back-up barrier methods of contraception must be utilized during treatment and for one month following discontinuation. Furthermore, modafinil inhibits CYP2C19 enzymes, which may elevate circulating levels of co-administered medications such as warfarin, phenytoin, diazepam, and omeprazole, necessitating dosage monitoring.

What to avoid while taking it: Concomitant use of alcohol and Vilafinil is strongly discouraged. The central nervous system interactions between modafinil and ethanol have not been fully established, and concurrent ingestion may lead to unpredictable cognitive impairment or altered sedation thresholds. Ingestion of excessive caffeine or other over-the-counter central nervous system stimulants should be limited to prevent heightened cardiovascular effects, such as tachycardia, elevated blood pressure, or severe restlessness.

If you skip a dose: If a scheduled morning dose is missed, it should be taken as soon as remembered on that same morning. However, if the omission is recognized late in the afternoon or evening, the missed dose should be skipped entirely to prevent nocturnal insomnia. Patients should return to their regular dosing schedule the following day. Taking a double dose to compensate for a missed tablet is contraindicated.

Storage and expiration: Vilafinil tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). Store the medication in its original container, tightly closed, and protected from excess heat, light, and moisture. Because modafinil is a controlled substance, it must be stored securely out of reach of children, domestic animals, and unauthorized individuals. Expired or unused medication should be disposed of via community take-back programs rather than household trash.

Common questions

Q: Does Vilafinil interfere with hormonal birth control efficacy?

A: Yes. Modafinil induces the CYP3A4 liver enzyme, which accelerates the clearance of estrogen and progestin components in hormonal contraceptives. This reduces the reliability of oral birth control pills, contraceptive patches, implants, and vaginal rings. Patients using hormonal methods must utilize an alternative or supplemental barrier method of contraception during treatment and for 30 days after stopping Vilafinil.

Q: Can Vilafinil be stopped abruptly, or does it require gradual tapering?

A: While modafinil does not typically cause severe physiological withdrawal symptoms comparable to classic amphetamines, abrupt discontinuation may cause a sudden return of severe daytime sleepiness and fatigue. Patients seeking to discontinue therapy should discuss a structured plan with their prescribing physician to manage underlying daytime somnolence.

Q: Is it safe to drive or operate machinery while taking Vilafinil?

A: Although Vilafinil is prescribed to reduce sleepiness, it may not restore completely normal levels of wakefulness. Patients may experience altered judgment, dizziness, or lingering sleepiness. Individuals should refrain from driving, operating heavy machinery, or engaging in hazardous tasks until they have observed how the drug affects their individual cognitive function and alertness.

Q: What steps should be taken if severe insomnia occurs?

A: Insomnia often results from taking the medication too late in the day. To minimize sleep disturbances, the dose should be taken early in the morning for narcolepsy or sleep apnea, or approximately one hour before shift work for shift work disorder. If insomnia persists despite proper timing, patients should consult their healthcare provider for dosage adjustments.

Q: How does Vilafinil differ from traditional amphetamine-based stimulants?

A: Vilafinil contains modafinil, which selectively targets brain regions responsible for wakefulness with lower affinity for dopamine release systems compared to classic stimulants like amphetamines or methylphenidate. Consequently, it presents a lower incidence of peripheral cardiovascular stimulation (such as severe tachycardia) and a lower potential for abuse, leading to its classification as a Schedule IV controlled substance.

In accordance with FDA guidelines and federal regulations, prescription medications must be used under direct clinical supervision.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

200 mg

Package

30 pills

,

60 pills

,

100 pills

,

200 pills

,

300 pills

,

500 pills

Ενεργός Ουσία